All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 5 read as filed from the record and 4 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2023-06-02.
From the record
Elicio Therapeutics, Inc.'s filings since 2017 show 2 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2022-12-22); an auditor change (8-K item 4.01, the latest 2023-06-02) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-10.6% a year over 3 filed years; profitable in 0 of 3.
From the record
Elicio Therapeutics, Inc.'s 3 filed years say what it did: revenue went from $3 million in fiscal 2020 to $2 million in fiscal 2022, down 10.6% a year; it rose in 1 of 2 years; the deepest fall was 92% from fiscal 2021 to fiscal 2022; net income was positive in 0 of 3 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 1.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Elicio Therapeutics, Inc.'s shareholder treatment is put at 1.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 12% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -2419%: lost 2419¢ per shareholder dollar. Leverage 94%: owes 94¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Elicio Therapeutics, Inc. lost about 2419 cents for every dollar of shareholders' money. Leverage: it owed about 94 cents per dollar of assets, and net share issuance: its share count grew 25.5% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 27% of 315 in its family; net margin -1225.9%.
From the record
Elicio Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $2 million in fiscal 2022 ranks in the bottom 29% by size; a net margin of -1225.9% ranks in the bottom 28%; revenue growth of -10.6% a year over the last 2 filed years ranks in the bottom 25% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 6.3/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Elicio Therapeutics, Inc.'s leadership is put at 6.3 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 37% of 415 in its family; the record of its people begins on 2023-06-05 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 3.4 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
SI estimate 6.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Elicio Therapeutics, Inc.'s room to expand is put at 6.1 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 39% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
bottom 33% of 306 in its family for growth drivers.
From the record
Elicio Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2022: revenue grew -10.6% a year over the last three filed years against -10.6% over all 3, speeding up (top 40% of its family); the newest year grew -91.9% (bottom 4%); research spending grew 11.2% a year (top 37%); capital spending grew -71% a year (bottom 4%) (its annual reports). Elicio Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 5.3/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Elicio Therapeutics, Inc.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made